Anne Langsted

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 17

Top Topics

Low Density Lipoprotein

Smoking Cessation

Clinical Practice

Cardiovascular Events

Top Venues

Current atherosclerosis reports

European journal of epidemiology

Clinical chemistry

Journal of internal medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Anders Berg Wulff, Børge Grønne Nordestgaard, Anne Langsted
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment. Current atherosclerosis reports (2024)
Anders Berg Wulff, Børge Grønne Nordestgaard, Anne Langsted
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment. Current atherosclerosis reports 26 (4) (2024)
Anne Langsted, Børge G Nordestgaard
Worldwide Increasing Use of Nonfasting Rather Than Fasting Lipid Profiles. Clinical chemistry 70 (7) (2024)
Anne Langsted, Børge G Nordestgaard
Worldwide Increasing Use of Nonfasting Rather Than Fasting Lipid Profiles. Clinical chemistry (2024)
Anders Berg Wulff, Børge Grønne Nordestgaard, Anne Langsted
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment. Current atherosclerosis reports 26 (4) (2024)
Takahito Doi, Anne Langsted, Børge Grønne Nordestgaard
Mass changes in remnant cholesterol and LDL cholesterol explain part of the results of gemfibrozil and non-gemfibrozil fibrate trials. Journal of internal medicine 295 (5) (2024)
Takahito Doi, Anne Langsted, Børge Grønne Nordestgaard
Mass changes in remnant cholesterol and LDL cholesterol explain part of the results of gemfibrozil and non-gemfibrozil fibrate trials. Journal of internal medicine 295 (5) (2024)
Anders Berg Wulff, Børge Grønne Nordestgaard, Anne Langsted
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment. Current atherosclerosis reports 26 (4) (2024)
Anders Berg Wulff, Børge Grønne Nordestgaard, Anne Langsted
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment. Current atherosclerosis reports 26 (4) (2024)
Takahito Doi, Anne Langsted, Børge Grønne Nordestgaard
Mass changes in remnant cholesterol and LDL cholesterol explain part of the results of gemfibrozil and non-gemfibrozil fibrate trials. Journal of internal medicine (2024)
Signe E J Hansen, Børge G Nordestgaard, Anne Langsted
Smoking as the most important risk factor for chronic pancreatitis in the general population. European journal of epidemiology (2023)
Signe E J Hansen, Børge G Nordestgaard, Anne Langsted
Smoking as the most important risk factor for chronic pancreatitis in the general population. European journal of epidemiology 38 (1) (2023)
Signe E J Hansen, Børge G Nordestgaard, Anne Langsted
Smoking as the most important risk factor for chronic pancreatitis in the general population. European journal of epidemiology 38 (1) (2023)
Signe E J Hansen, Børge G Nordestgaard, Anne Langsted
Smoking as the most important risk factor for chronic pancreatitis in the general population. European journal of epidemiology 38 (1) (2023)
Signe E J Hansen, Anette Varbo, Børge G Nordestgaard, Anne Langsted
Hypertriglyceridemia-Associated Pancreatitis: New Concepts and Potential Mechanisms. Clinical chemistry (2023)
Camilla D L Johannesen, Martin B Mortensen, Anne Langsted, Børge Grønne Nordestgaard
ApoB and Non-HDL Cholesterol Versus LDL Cholesterol for Ischemic Stroke Risk. Annals of neurology 92 (3) (2022)
Anne Langsted, Børge Grønne Nordestgaard
Value of Genetic Testing for Lipoprotein(a) Variants. Circulation. Genomic and precision medicine 15 (2) (2022)